Meeting
2018 Gastrointestinal Cancers Symposium
Clinical impact of diverting ileostomy on the dose intensity of adjuvant chemotherapy for colorectal cancer.
Authors
Shusuke Yagi
The Cancer Institute Hospital, Tokyo, Japan
Shusuke Yagi , Eiji Shinozaki , Keisho Chin , Mitsukuni Suenaga , Daisuke Takahari , Mariko Ogura , Takashi Ichimura , Takeru Wakatsuki , Masato Ozaka , Izuma Nakayama , TOMOHIRO MATSUSHIMA , Hiroki Osumi , Kensei Yamaguchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 867)
DOI
10.1200/JCO.2018.36.4_suppl.867
Abstract #
867
Poster Bd #
P19
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
The influence of adjuvant chemotherapy dose intensity on overall survival in resected colon cancer: A multicenter retrospective analysis.
First Author: Suganija Lakkunarajah
Poster
2022 ASCO Annual Meeting
Cost-effectiveness of adjuvant chemotherapy for patients with high-risk stage II and stage III colon cancer in South Africa.
First Author: Yoanna S Pumpalova
Poster
2020 ASCO Virtual Scientific Program
TRACC: Tracking mutations in cell-free DNA to predict relapse in early colorectal cancer—A randomized study of circulating tumour DNA (ctDNA) guided adjuvant chemotherapy versus standard of care chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer (CRC).
First Author: Gayathri Anandappa
Poster
2019 ASCO Annual Meeting
POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer—A phase III randomized study.
First Author: David Lau